Global Neuropathy Pain Treatment Market to grow at a CAGR of 5.85% during the period 2017 - 2021; Finds New Report

Report forecast the global neuropathy pain treatment market to grow at a CAGR of 5.85% during the period 2017-2021.

Neuropathic pain is a complex, chronic pain condition that is accompanied by tissue injury. In neuropathic pain, the nerve fibers may be damaged, dysfunctional, or injured. These nerve fibers send incorrect signals to other pain centers. The impact of nerve fiber injury creates a change in nerve function at the site of injury and areas surrounding the injury.

The report covers the present scenario and the growth prospects of the global neuropathy pain treatment market for 2017-2021. To calculate the market size, the report considers the indications of neuropathic pain such as diabetic neuropathy, chemotherapy-induced neuropathy pain, postherpetic neuralgia, and others.

The market is divided into the following segments based on geography:

• Americas
• APAC
• EMEA

According to the report, one driver in market is presence of large patient pool. The presence of large patient pool with neuropathic pain is expected to fuel the market growth. Neuropathic pain is associated with various disorders such as diabetic neuropathy, chemotherapy-induced pain, shingles, and herniated disk. There has been growing cases of the population with these disorders. For instance, according to the CDC 2014 statistics, 29.1 million individuals in the US have diabetes in 2014. Out of this, around 6-7 individuals per 1,000 individuals are suffering from diabetic neuropathy. Also, the increasing individuals preferring chemotherapy for cancer treatment is fueling the cases of chemotherapy-induced pain. For instance, according to the CDC, about 650,000 individuals with cancer receive chemotherapy in outpatient oncology clinics in the US. In addition, the increasing incidence of shingles is expected to drive the market growth. According to the CDC, the incidence of shingles is approximately four per 1,000 US population annually. Further, the disease is more prevalent in ages 60 and above. The incidence among individuals 60 years of age and above is 10 cases per 1,000 US population annually. Overall, there are an estimated one million cases of herpes zoster in the US annually. Such scenario will lead to an increase in adoption of neuropathic pain drugs, which will, in turn, drive the market growth.

Further, the report states that one challenge in market is patent expiries hamper the growth prospects. The patent expiry of major approved drugs is expected to impact the market adversely and is anticipated to slow down its growth during the forecast period. Patent expiry of a drug often results in the loss of an exclusive market for that drug, leading to a rapid decline in sales. For instance, Eli Lilly's Cymbalta lost its US patent protection in December 2013, allowing the US FDA to approve its generic versions for market use. Cymbalta lost its data package protection in European countries in 2014. Pfizer's LYRICA for neuropathic pain is set to expire in 2017 and will fuel the launch of generics after this period. Already for other indications, Consilient Health, a manufacturer of generic and specialty pharma products launched Rewisca (a generic version of LYRICA) with a cost less than 25% than branded LYRICA. Although the companies cannot market generic version for LYRICA before the expiry period, they may infringe the patent. This will have an adverse effect on the sales of LYRICA. In addition, many other companies are looking to launch the generic version of LYRICA for the treatment of neuropathic pain. This scenario is expected to affect the market growth.

Global Neuropathy Pain Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the global neuropathy pain treatment market: Depomed, Eli Lilly, Endo International, and Pfizer.

Other Prominent Vendors in the market are: Allodynic Therapeutics, Arbor Pharmaceuticals, Astellas Pharma, Aurobindo Pharma, Avanir Pharmaceuticals, Biogen, CAPNIA, Centrexion Therapeutics, Cerecor, ContraVir Pharmaceuticals, Crescita Therapeutics, DAEWOONG, Daiichi Sankyo, Dr. Reddy's Laboratories, Eisai Pharmaceuticals, Grünenthal, GlaxoSmithKline, Hydra Biosciences, Immune Pharmaceuticals, Jiangsu Hengrui Medicine, Lexicon Pharmaceuticals, Lupin, Mallinckrodt, Midatech Pharma, Neurotune, Newron Pharmaceuticals, Novaremed, Novartis, PledPharma, Premier Biomedical, Regeneron, Samyang Biopharmaceuticals, Sienna Biopharmaceuticals, Sun Pharma, Teva Pharmaceutical Industries, TheraVasc, TORAY INDUSTRIES, Torrent Pharmaceuticals, UCB Pharma, VanWorld Pharmaceutical (a subsidiary of Vanway), VistaGen Therapeutics, WEX Pharmaceuticals, WINSTON PHARMACEUTICALS, Wockhardt, and Yuhan Corporation.

Market driver

• Focus toward the development of novel therapeutics for postherpetic neuralgia.
• For a full, detailed list, view our report

Market challenge

• High unmet needs in the treatment of neuropathic pain affects the adoption rates.
• For a full, detailed list, view our report

Market trend

• Increasing mergers and acquisitions would lead to further consolidation.
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Spanning over 70 pages and 45 Exhibits “Global Neuropathy Pain Treatment Market 2017 - 2021” report covers Executive summary, Scope of the report, Market research methodology, Introduction, Market landscape, An overview of neuropathic pain, Pipeline landscape, Market segmentation by indication, Market segmentation by drug class, Geographical segmentation, Decision framework, Drivers and challenges, Market trends, Vendor landscape, Key vendor analysis, Appendix.

For more information Visit at: http://mrr.cm/UTL

Related Reports;

Global Factor IX Deficiency Treatment Market 2017-2021 - Visit at - http://mrr.cm/UTb

Global Colonoscopy Devices Market 2017-2021 - Visit at - http://mrr.cm/UTE